These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33854239)

  • 21. [Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer].
    Qin Q; Ren Y; Zhong D
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):176-181. PubMed ID: 32102134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMBRA1 interplay with cullin E3 ubiquitin ligases regulates autophagy dynamics.
    Antonioli M; Albiero F; Nazio F; Vescovo T; Perdomo AB; Corazzari M; Marsella C; Piselli P; Gretzmeier C; Dengjel J; Cecconi F; Piacentini M; Fimia GM
    Dev Cell; 2014 Dec; 31(6):734-46. PubMed ID: 25499913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.
    Zhang J; Xu K; Liu P; Geng Y; Wang B; Gan W; Guo J; Wu F; Chin YR; Berrios C; Lien EC; Toker A; DeCaprio JA; Sicinski P; Wei W
    Mol Cell; 2016 Jun; 62(6):929-942. PubMed ID: 27237051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting CDK4 and CDK6: From Discovery to Therapy.
    Sherr CJ; Beach D; Shapiro GI
    Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells.
    The I; Ruijtenberg S; Bouchet BP; Cristobal A; Prinsen MB; van Mourik T; Koreth J; Xu H; Heck AJ; Akhmanova A; Cuppen E; Boxem M; Muñoz J; van den Heuvel S
    Nat Commun; 2015 Jan; 6():5906. PubMed ID: 25562820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
    Saab R; Bills JL; Miceli AP; Anderson CM; Khoury JD; Fry DW; Navid F; Houghton PJ; Skapek SX
    Mol Cancer Ther; 2006 May; 5(5):1299-308. PubMed ID: 16731763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
    VanArsdale T; Boshoff C; Arndt KT; Abraham RT
    Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
    Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
    Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of epidermal growth factor receptor tyrosine kinase inhibitor resistance via Ambra1-mediated autophagy in non-small cell lung cancer.
    Chen YH; Yang Y; Xu LJ; Deng Y; Fu JW
    J Physiol Pharmacol; 2023 Jun; 74(3):. PubMed ID: 37661184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.
    Jiang B; Wang ES; Donovan KA; Liang Y; Fischer ES; Zhang T; Gray NS
    Angew Chem Int Ed Engl; 2019 May; 58(19):6321-6326. PubMed ID: 30802347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin D degradation by E3 ligases in cancer progression and treatment.
    Qie S; Diehl JA
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):159-170. PubMed ID: 32006569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
    Bouclier C; Simon M; Laconde G; Pellerano M; Diot S; Lantuejoul S; Busser B; Vanwonterghem L; Vollaire J; Josserand V; Legrand B; Coll JL; Amblard M; Hurbin A; Morris MC
    Theranostics; 2020; 10(5):2008-2028. PubMed ID: 32104498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.
    Goto Y; Koshizuka K; Ando T; Izumi H; Wu X; Sato K; Ishikawa T; Ford K; Feng X; Wang Z; Arang N; Allevato MM; Kishore A; Mali P; Gutkind JS
    Cancer Res Commun; 2024 Jul; 4(7):1850-1862. PubMed ID: 38954773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.
    Zhang C; Stockwell SR; Elbanna M; Ketteler R; Freeman J; Al-Lazikani B; Eccles S; De Haven Brandon A; Raynaud F; Hayes A; Clarke PA; Workman P; Mittnacht S
    Oncogene; 2019 Jul; 38(30):5905-5920. PubMed ID: 31296956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNF2 is recruited by WASH to ubiquitinate AMBRA1 leading to downregulation of autophagy.
    Xia P; Wang S; Huang G; Du Y; Zhu P; Li M; Fan Z
    Cell Res; 2014 Aug; 24(8):943-58. PubMed ID: 24980959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.